Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

The Journal of clinical investigation - 1 Sept 2007

Shah Neil P, Skaggs Brian J, Branford Susan, Hughes Timothy P, Nicoll John M, Paquette Ronald L, Sawyers Charles L

Abstract excerpt

Molecularly targeted kinase inhibitor cancer therapies are currently administered sequentially rather than simultaneously. We addressed the potential long-term impact of this strategy in patients with chronic myelogenous leukemia (CML), which is driven by the fusion oncogene BCR-ABL. Analysis of BCR-ABL genotypes in CML patients who relapsed after sequential treatment with the ABL inhibitors imatinib and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Proto-Oncogene Proteins c-abl

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 17710227
DOI: 10.1172/JCI30890
PMCID: PMC1940237

Genes

BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.PMID 17710227Read ↗

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.Semantic proximity Read ↗

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Semantic proximity Read ↗

Overriding imatinib resistance with a novel ABL kinase inhibitor.Semantic proximity Read ↗

SGX393 inhibits the CML mutant Bcr-Abl T315I and preempts in vitro resistance when combined with nilotinib or dasatinibSemantic proximity Read ↗

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in checkSemantic proximity Read ↗

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.Semantic proximity Read ↗

Resistance to targeted therapy in chronic myelogenous leukemia.Semantic proximity Read ↗

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.Semantic proximity Read ↗

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.Semantic proximity Read ↗

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.Semantic proximity Read ↗

Resistance in the land of molecular cancer therapeutics.Semantic proximity Read ↗

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.